Union Square Park Capital Management’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-253,770
Closed -$2.52M 157
2021
Q4
$2.52M Buy
+253,770
New +$2.52M 0.79% 33

Other funds holding GRNA

Union Square Park Capital Management's GRNA Position: Q1 2022 in Review

Union Square Park Capital Management sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q1 2022, closing a stake of 253,770 shares — an estimated $2.52M sold.

Union Square Park Capital Management first reported a position in GRNA in Q4 2021 and held it in 1 quarter. The position peaked at $2.52M in Q4 2021. 39 funds tracked by Wall St. Rank hold GRNA as of Q1 2022.

  • Union Square Park Capital Management reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q1 2022 after selling out during the quarter.
  • Union Square Park Capital Management sold 253,770 GreenLight Biosciences Holdings, PBC Common Stock shares in Q1 2022, an estimated $2.52M.
  • Union Square Park Capital Management first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q4 2021 and held it in 1 quarter.
  • Union Square Park Capital Management's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $2.52M in Q4 2021.
  • 39 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q1 2022.

Based on Union Square Park Capital Management's 13F filing for Q1 2022, filed 16 May 2022.